Mobile

4T study Treating to Target in Type 2 Diabetes A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin versus a T...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000514-38

4T study Treating to Target in Type 2 Diabetes A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin versus a Twice Daily Insulin Mixture versus a Meal-time Rapid-Acting Insulin in Subjects with Type 2 Diabetes Inadequately Controlled on Therapy with Oral Agents, and Assessing the Requirement for more Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, their Efficacy and Durability

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Over 12 months: to compare the ability of three different single insulin formulation regimens to achieve good glycaemic control, defined as HbA1C levels ≤6.5 %, when added to current oral anti-diabetic drug (OAD) treatment in subjects with inadequately controlled type 2 diabetes.

Critère d'inclusion

  • Type 2 Diabetes

Liens